The Effects of Selenium Supplementation in the Treatment of Autoimmune Thyroiditis: An Overview of Systematic Reviews
Nutrients · 2023
DOI: 10.3390/nu15143194 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Nutrients, 2023. Verfasst von Yong-Sheng Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Evidence-Based Social Science Research Center/Health Technology Assessment Center, School of Public Health, Lanzhou University, Lanzhou 730000, China. Hauptthemen laut MEDLINE: Thyroiditis, Autoimmune, Selenium, Hashimoto Disease. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Major Project of the National Social Science Fund of China.
Abstract (Originalsprache)
Objective
The available evidence on selenium supplementation in the treatment of autoimmune thyroiditis (AIT) was inconclusive. This research serves to assess the effects of selenium supplementation in the treatment of AIT.
Methods
Online databases including PubMed, Web of Science, Embase, and the Cochrane Library were searched from inception to 10 June 2022. The AMSTAR-2 tool was used to assess the methodological quality of included studies. The information on the randomized controlled trials of the included studies was extracted and synthesized. The GRADE system was used to assess the certainty of evidence.
Results
A total of 6 systematic reviews with 75 RCTs were included. Only one study was rated as high quality. The meta-analysis showed that in the levothyroxine (LT4)-treated population, thyroid peroxidase antibody (TPO-Ab) levels decreased significantly in the selenium group at 3 months (SMD = −0.53, 95% CI: [−0.89, −0.17], p < 0.05, very low certainty) and 6 months (SMD = −1.95, 95% CI: [−3.17, −0.74], p < 0.05, very low certainty) and that thyroglobulin antibody (Tg-Ab) levels were not decreased. In the non-LT4-treated population, TPO-Ab levels decreased significantly in the selenium group at 3 and 6 months and did not decrease at 12 months. Tg-Ab levels decreased significantly in the selenium group at 3 and 6 months and did not decrease at 12 months. The adverse effects reported in the selenium group were not significantly different from those in the control group, and the certainty of evidence was low.
Conclusion
Although selenium supplementation might reduce TPO-Ab levels at 3 and 6 months and Tg-Ab levels at 3 and 6 months in the non-LT4-treated population, this was based on a low certainty of evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Evidence-Based Social Science Research Center/Health Technology Assessment Center, School of Public Health, Lanzhou University, Lanzhou 730000, China.
- Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou University, Lanzhou 730000, China.
- Gansu Healthcare Security Administration, Lanzhou 730000, China.
Förderung
- The Major Project of the National Social Science Fund of China
Zitieren
APA
Wang, Y. S., Liang, S. S., Ren, J. J., Wang, Z. Y., Deng, X. X., Liu, W. D., Yan, Y. L., Song, G. H., & Li, X. X. (2023). The Effects of Selenium Supplementation in the Treatment of Autoimmune Thyroiditis: An Overview of Systematic Reviews. Nutrients. https://doi.org/10.3390/nu15143194
Vancouver
Wang YS, Liang SS, Ren JJ, Wang ZY, Deng XX, Liu WD, et al. The Effects of Selenium Supplementation in the Treatment of Autoimmune Thyroiditis: An Overview of Systematic Reviews. Nutrients. 2023. doi:10.3390/nu15143194
BibTeX
@article{Wang2023,
author = {Wang, Yong-Sheng and Liang, Shan-Shan and Ren, Jun-Jie and Wang, Zi-Yi and Deng, Xin-Xin and Liu, Wen-Di and Yan, Yi-Long and Song, Gui-Hang and Li, Xiu-Xia},
title = {The Effects of Selenium Supplementation in the Treatment of Autoimmune Thyroiditis: An Overview of Systematic Reviews},
journal = {Nutrients},
year = {2023},
doi = {10.3390/nu15143194}
}
EUVIMED